stockrowWhat it does
Rhythm Pharmaceuticals is a biopharmaceutical company focused on rare diseases that affect hunger and body weight. Its marketed medicine, IMCIVREE, is designed for people whose severe obesity is associated with disorders of the melanocortin-4 receptor, or MC4R, pathway. This pathway helps regulate hunger, food intake and energy expenditure. When it is impaired by a genetic condition or an injury, patients can experience severe obesity and hyperphagia—an insatiable hunger accompanied by persistent food-seeking behavior.
IMCIVREE activates the MC4R receptor. In the United States, it is approved for weight reduction and long-term weight management in eligible adults and children with Bardet-Biedl syndrome or certain deficiencies involving the POMC, PCSK1 or LEPR genes. The medicine is also available for acquired hypothalamic obesity, a condition that can follow injury to the part of the brain involved in weight regulation.
Rhythm is developing other medicines aimed at the same pathway. Bivamelagon is an oral drug candidate, while RM-718 is designed as a weekly injection. The company is studying treatments for hypothalamic obesity, Prader-Willi syndrome and other genetic disorders affecting the pathway.
Rhythm was founded in 2008 and is headquartered in Boston. David P. Meeker is chairman, chief executive officer and president.
How it makes money
Rhythm earns product revenue from sales of IMCIVREE. It holds worldwide rights to the medicine and has built its own marketing and sales infrastructure in the United States, with commercial infrastructure in several European markets and the United Kingdom. Sales depend on identifying eligible patients, obtaining prescriptions and securing payment or reimbursement. In some markets, the company also makes named-patient sales or sells through paid early-access programs.
For FY2025, revenue in its single reportable segment was $189.8 million; for Q3 2026, global net revenue was $92.1 million.
The company has one reportable segment. FY2025 net product revenue was $194.8 million, compared with $130.1 million in FY2024. FY2025 license revenue was −$5.0 million. Product revenue therefore exceeded total revenue in that year.
Patients can remain on therapy over time: IMCIVREE’s U.S. approval for certain genetic conditions includes maintaining weight reduction long term. The company said the vast majority of acquired hypothalamic obesity patients had remained on treatment, although that launch was still early. Continued sales depend on patients remaining on therapy as well as new patients starting it.
In Q3 2026, the U.S. acquired hypothalamic obesity launch was the primary driver of sequential revenue growth. The company said shipments to its U.S. specialty pharmacy outpaced patient dispensing during the quarter. International revenue can also vary with shipments to named-patient sales markets.
| Product or service | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Product revenue, net | $194.8 million | 102.6% | 49.7% |
| License revenue | −$5.0 million | −2.64% | — |
Customers and how it sells
Rhythm’s medicines reach patients through physicians and healthcare systems, with third-party payers playing a role in access. Its field teams engage physicians who treat people with severe obesity, while genetic testing and disease-awareness programs help identify patients with eligible conditions. One customer accounted for 69.0% of FY2025 revenue; that figure does not identify the customer.
IMCIVREE is marketed in the United States, the European Union, the United Kingdom, Canada and other countries for certain rare MC4R pathway diseases. In 2026, Rhythm expanded its acquired hypothalamic obesity business: the medicine received European authorization in May and launched for that condition in Japan in October. Physicians in France and Italy have also treated hypothalamic obesity patients through paid early-access programs.
Through the first two quarters of the U.S. acquired hypothalamic obesity launch, Rhythm received more than 700 patient start forms, including forms for clinical-trial patients. It said start forms had come from more than 500 prescribers since launch. These forms measure requests to start treatment, not necessarily patients receiving reimbursed therapy.
At the end of Q3 2026, the company said acquired hypothalamic obesity coverage policies affected approximately 60% of Medicaid covered lives and 75% of commercial covered lives. Access and reimbursement arrangements vary by country.
| Segment | Revenue, FY2025 | Share | Change on the year |
|---|---|---|---|
| Single reportable segment | $189.8 million | 100.0% | 45.8% |
Suppliers and costs
Rhythm uses contract manufacturing organizations to produce clinical and commercial-grade setmelanotide. It also pays outside research organizations and consultants for research, preclinical work and drug development. Other research costs include employees, laboratory supplies, genetic sequencing and clinical study materials. The company expenses research and development costs as they are incurred.
Some IMCIVREE inventory was manufactured before approval, with most of those manufacturing costs recorded as research and development expenses in earlier periods. Rhythm expected cost of sales to rise in 2026 as it sold more inventory produced after it began capitalizing commercial manufacturing costs. In Q3 2026, cost of goods sold was 13.2% of product revenue, driven primarily by materials and royalty payments.
Rhythm amended its bivamelagon license with LG Chem. It agreed to pay $350 million in installments over four years in exchange for a reduced royalty obligation, with the reduced 1% flat royalty assuming U.S. approval of bivamelagon. The agreement also includes development and commercial milestone obligations. Rhythm said the present value of the fixed payments would be recognized as research and development expense in the fourth quarter.
- Revenue$189.8M
- Cost of revenue−$19.5M
- Research and development−$167.3M
- Selling, general and administrative−$194.9M
- Operating income−$192.0M
Competitive position
Rhythm competes for the treatment of rare obesity and hunger disorders, as well as for patients in clinical trials. The company says IMCIVREE is the only approved weight-management treatment specifically for patients with obesity due to Bardet-Biedl syndrome or POMC, PCSK1 or LEPR deficiencies. It says general-obesity medicines, including drugs targeting GLP-1 and GIP receptors, do not specifically restore the impaired MC4R pathway. General-obesity medicines and surgery can nevertheless be used in some patients with these diseases.
Other companies have early-stage programs exploring MC4R agonists, most in preclinical or discovery stages; Rhythm does not name those companies. In Prader-Willi syndrome, Rhythm says there is an approved therapy in the United States, and patients taking VYKAT have been included in its current trial. Clinical trials in related therapeutic areas also compete for eligible patients.
Our reading: IMCIVREE’s specific approvals provide a meaningful position in its current rare-disease indications, but they do not prevent other approaches or future entrants from competing for patients.
Our reading: Rhythm’s genetic testing, sequencing database and physician outreach support patient identification, although the rarity and underdiagnosis of these diseases make that work ongoing. Its development programs could extend that position, but their commercial use depends on trial results and approvals.
Growth opportunities
Rhythm’s growth plans center on finding and treating more patients in approved indications, expanding IMCIVREE into additional diseases and countries, and developing new MC4R medicines. The acquired hypothalamic obesity launch adds a patient group whose condition can result from injury rather than an inherited genetic disorder.
The company estimates approximately 10,000 people in the United States live with acquired hypothalamic obesity, with similar prevalence in Europe and between 5,000 and 8,000 patients in Japan. These are Rhythm’s prevalence estimates, not counts of diagnosed or treated patients. The company also estimates approximately 4,600 to 7,500 U.S. patients in its initial FDA-approved genetic indications.
Rhythm is studying setmelanotide in additional genetically defined MC4R pathway diseases and in congenital hypothalamic obesity. For Prader-Willi syndrome, it plans its first Phase 3 trial with bivamelagon and expects to develop both bivamelagon and RM-718 in the disease. The company also plans a Phase 3 bivamelagon study in hypothalamic obesity, using body mass index as the primary endpoint.
Geographic expansion requires separate regulatory and reimbursement work. After the Japanese launch, Rhythm said it had identified more than 1,000 potentially eligible patients through hospital engagement. In Europe, it submitted acquired hypothalamic obesity reimbursement dossiers in France, Italy, the United Kingdom, Spain and the Netherlands.
- $3.2MFY2021
- $23.6MFY2022
- $77.4MFY2023
- $130.1MFY2024
- $189.8MFY2025
Structural risks
- Commercial access: Revenue depends on continued physician and payer acceptance, patient identification, reimbursement and the company’s ability to make IMCIVREE available. Diagnosis and changes in insurance can delay treatment or reimbursement.
- Clinical and regulatory development: Positive earlier trial results may not predict later results. New indications and medicines require trials and regulatory approvals, and other studies can compete for eligible patients.
- Patient estimates: The rarity of genetic MC4R pathway diseases and limited patient registries make prevalence difficult to establish precisely. Rhythm says its projections may significantly under- or overestimate addressable populations.
- Manufacturing and supply: Revenue depends in part on successfully manufacturing setmelanotide or contracting with others to do so. Drug supply and formulation availability also affect development choices for its next-generation medicines.
- Funding and obligations: Rhythm reported a net loss for FY2025 and expects significant expenses. It has financing obligations and agreed fixed payments to LG Chem; it also says it may be unable to obtain additional funding or arrangements on favorable terms when needed.
Bottom line
Our reading
Rhythm is a rare-disease drug company built around one marketed medicine and a pipeline aimed at the same biological pathway. Our reading: broader indications and geographic launches give it routes to reach more patients, but growth depends on finding patients, winning reimbursement and advancing drugs through trials. Its continuing losses and financing commitments also matter alongside rising product sales.